Test article and method for performing blood coagulation assays

• US 5,580,744 A
• Filed: 10/03/1994
• Issued: 12/03/1996
• Est. Priority Date: 04/27/1992
• Status: Expired due to Term

• Current Assignee: Beckman Coulter Incorporated (Danaher Corporation)
• Original Assignee: Avocet Medical, Inc.
• Inventors: Zweig, Stephen E.
• Primary Examiner(s): Gitomer, Ralph J.
• Application Number:
  US08/316,749
• Time in Patent Office: 792 Days
• Field of Search: 435/13, 435/176, 435/180, 435/182, 422/56, 422/57, 422/60, 436/69, 530/381, 530/384
• US Class Current: 435/13
• CPC Class Codes: C12Q 1/56 involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
• CPC Class Codes: C12Q 2337/22 7-Amino-4-methylcoumarin, i.e. AMC, MCA
• CPC Class Codes: G01N 33/523 the element being adapted for a specific analyte
• CPC Class Codes: G01N 33/86 involving blood coagulating time or factors, or their receptors

Abstract

A test article for determining coagulation capability in a blood sample comprises a porous membrane having a coagulation initiator and substrate impregnated therein. The pore dimensions and composition of the membrane may be selected so that only blood plasma can pass into the interior of the membrane, where coagulation is initiated. Alternatively, the substrate may be selected to have an emission and/or excitation wavelength which is not absorbed by hemoglobin. The substrate is activated by a component of the coagulation pathway, typically thrombin, and produces a detectable signal upon activation. By utilizing membrane matrix materials which are substantially free from interference with the coagulation pathway, accurate results can be achieved.

Claims

1. A test article comprising:

a single permeable membrane having an application face and an opposite indicator face, said membrane being substantially free from interference with a coagulation pathway;

a coagulation initiator impregnated within the membrane; and

a substrate impregnated within the membrane, which substrate produces a detectable signal upon activation by a component of the coagulation pathway;

whereby whole blood may be applied to the application face of the membrane and a detectable signal is produced on the indicator face as a result of production of the component of the coagulation pathway.

2. A test article as in claim 1, wherein the permeable membrane is composed of a hydrophilic, non-swellable material which is free from interference with the coagulation pathway.

3. A test article as in claim 2, wherein the material is polysulfone.

4. A test article as in claim 3, wherein the polysulfone has an asymmetric structure.

5. A test article as in claim 1, wherein the permeable membrane is hydrophilic, non-swellable material which has been blocked with protein to inhibit interference with the coagulation pathway.

6. A test article as in claim 1, wherein the coagulation initiator initiates the extrinsic coagulation pathway.

7. A test article as in claim 6, wherein the coagulation initiator is selected from the group consisting of thromboplastin, or other factor VII activating substances.

8. A test article as in claim 1, wherein the coagulation initiator initiates the intrinsic coagulation pathway.

9. A test article as in claim 8, wherein the coagulation initiator is selected from the group consisting of ellagic acid, kaolin, silica or other factor XII activating substances.

10. A test article as in claim 1, wherein the coagulation pathway component which activates the substrate is thrombin, and the substrate is a thrombin substrate.

11. A test article as in claim 10, wherein the thrombin substrate is a peptide cleavably attached to a reporter molecule, where thrombin binds the peptide and cleaves the reporter molecule from the peptide to produce the detectable signal.

12. A test article as in claim 11, wherein the detectable fluorescent signal has a wavelength which is absorbed by hemoglobin, and wherein the permeable membrane has a pore and size distribution geometry which excludes red blood cell penetration from the application face into the membrane.

13. A test article as in claim 11, wherein the detectable signal is a detectable fluorescent signal, having an emission wavelength which is not absorbed by hemoglobin.

14. A test article as in claim 13, wherein the substrate has an excitation wavelength which is not absorbed by hemoglobin.

15. A test article as in claim 14, wherein the fluorescent signal has an emission wavelength longer than 600 nm and the excitation wavelength is longer than 600 nm.

16. A test article as in claim 14, wherein the substrate is rhodamine-110.

17. A test article as in claim 1, further comprising a buffer impregnated within the membrane which maintains a pH compatible with the coagulation pathway and the permeable membrane.

18. A test article as in claim 1, further comprising calcium impregnated within the membrane.

19. A test article as in claim 1, further comprising a pigment impregnated within the membrane.

20. A test article as in claim 1, further comprising a flow control agent impregnated within the membrane.

21. The test article of claim 1 wherein the detectable signal is selected from the group consisting of a fluorescent signal and a chemiluminescent signal.

32. A method as in claim 21, wherein the substrate produces a fluorescent signal which is absorbed by hemoglobin, wherein the permeable membrane has a pore and size distribution geometry which excludes red blood cell penetration from the application face into the membrane.

22. A inethod for determining coagulation capability of a patient, said method comprising:

applying a whole blood sample to an application face of a permeable membrane, wherein the membrane is substantially free from interference with a coagulation pathway and wherein a coagulation initiator and a substrate which produces a detectable signal upon activation by a component of the coagulation pathway proteolytic enzyme are impregnated within the membrane; and

detecting the signal at the indicator face of the membrane, wherein the indicator face is laterally opposed to the application face and the signal results from production of the coagulation pathway proteolytic enzyme within the membrane which had been initiated by interaction of the coagulation initiator with the blood sample.

23. A method as in claim 22, wherein the blood sample is not measured prior to applying.

24. A method as in claim 23, wherein the blood sample is obtained by a finger prick.

25. A method as in claim 22, performed at room temperature.

26. A method as in claim 22, performed at a controlled temperature.

27. A method as in claim 22, wherein the detectable signal is temperature compensated.

28. A method as in claim 22, wherein the detectable signal is a fluorescent signal which has a wavelength which is not absorbed by hemoglobin.

29. A method as in claim 28, wherein the substrate has an excitation wavelength which is not absorbed by hemoglobin.

30. A method as in claim 28, wherein the fluorescent signal has a wavelength longer than 600 nm and the excitation wavelength is longer than 600 nm.

31. A method as in claim 30, wherein the substrate is rhodamine - 110.

33. The method of claim 22 wherein the detectable signal is selected from the group consisting of a fluorescent signal and a chemiluminescent signal.